Sign in

    Chris Bialas

    Research Analyst at H.C. Wainwright & Co.

    Chris Bialas is an Equity Research Associate at H.C. Wainwright & Co., specializing in biotechnology and life sciences equities. He has covered companies such as Protagonist Therapeutics, Dare Bioscience, and Trevena Inc., contributing to investment assessments through detailed earnings call involvement and financial analysis. Bialas joined H.C. Wainwright after prior experience at Incyte, where he further honed his analytical skills within the biotech sector. His professional credentials include active participation in industry research and earnings forums, with demonstrated expertise in evaluating growth-stage therapeutics companies.

    Chris Bialas's questions to Protagonist Therapeutics (PTGX) leadership

    Chris Bialas's questions to Protagonist Therapeutics (PTGX) leadership • Q1 2020

    Question

    Chris Bialas, on behalf of Doug Tsao from H.C. Wainwright & Co., asked for more details about the observations in the beta-thalassemia trial that led to the decision to discontinue its development.

    Answer

    President and CEO Dinesh Patel explained that the company's strategy was to pursue multiple proof-of-concept studies and select a 'winner,' which is now clearly polycythemia vera. He noted that the beta-thalassemia data is currently under embargo but will be presented at an upcoming medical conference. Chief Medical Officer Dr. Samuel Saks emphasized that the decision was driven by the outstandingly positive PV data, not by negative findings in the beta-thalassemia trial, stating, 'we were really reacting to the positive here.'

    Ask Fintool Equity Research AI

    Chris Bialas's questions to Protagonist Therapeutics (PTGX) leadership • Q1 2020

    Question

    Chris Bialas, on behalf of Doug Tsao from H.C. Wainwright & Co., asked for more details regarding the clinical observations in the beta-thalassemia trial that led to the decision to discontinue its development.

    Answer

    President and CEO Dinesh Patel explained that the company's strategy was to identify a 'winner' from its multiple proof-of-concept studies, and polycythemia vera emerged as the clear lead indication. He noted that beta-thalassemia data is under embargo but will be presented at a future medical conference. Chief Medical Officer Samuel Saks reinforced this, stating the decision was a proactive response to the 'outstanding' and compelling data from the PV trial, rather than a reaction to negative results from the beta-thalassemia study.

    Ask Fintool Equity Research AI